A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type?

Table 5

Mean optical density of elastogenesis and degradation markers in anetoderma.

Group	Disease duration	Epidermis					Dermis
		Elastin	Fibrillin	MMP-2	MMP-9	TIMP-1	Elastin	Fibrillin	MMP-2	MMP-9	TIMP-1
Case 1, (protruding lesion)	12 months	0.00	71.87 ± 4.16	130.96 ± 13.05	104.23 ± 4.88	103.10 ± 12.71	22.54 ± 4.47	50.91 ± 3.29	88.19 ± 6.66	102.66 ± 11.57	51.75 ± 14.67
Control 1	NA	0.00	108.30 ± 19.12	125.98 ± 6.45	103.40 ± 6.06	81.71 ± 2.07	119.46 ± 7.15	74.32 ± 10.73	45.30 ± 25.72	8.63 ± 7.66	70.37 ± 13.62
Case 2, (protruding lesion)	1 week	0.00	56.16 ± 8.75	62.39 ± 10.45	107.69 ± 8.14	100.27 ± 6.46	39.62 ± 5.21	19.67 ± 15.86	83.16 ± 16.92	80.49 ± 7.18	42.00 ± 8.08
Control 2	NA	0.00	56.68 ± 10.56	44.45 ± 25.07	100.70 ± 5.78	49.29 ± 6.89	65.13 ± 33.51	25.72 ± 13.25	23.26 ± 13.42	43.88 ± 8.85	25.10 ± 3.25
Case 3, (indented lesion)	18.7 months	0.00	88.86 ± 15.5	72.08 ± 5.55	100.79 ± 7.16	95.22 ± 15.34	132.99 ± 7.19	89.33 ± 43.52	32.73 ± 16.18	77.28 ± 39.22	58.03 ± 4.65
Control 3	NA	0.00	99.68 ± 2.81	98.22 ± 4.99	53.35 ± 18.21	114.52 ± 16.75	159.44 ± 16.87	112.91 ± 57.10	125.58 ± 24.57	55.27 ± 8.08	109.37 ± 6.62
Normal control	NA	0.00	124.89 ± 5.90	92.93 ± 9.45	29.29 ± 3.29	108.33 ± 11.59	148.47 ± 8.33	103.03 ± 10.37	104.82 ± 13.92	72.08 ± 12.39	139.56 ± 28.57

NA: not applicable.